entertainment -WSS

entertainment

author：Wikipedia 2025-09-06 03:55:47 - browse：213

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Congress might make insulin pumps more accessible to the blind

WSS

Why Eli Lilly’s earnings didn’t quite live up to the hype

Juul documents reveal insider tactics on political lobbying

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Report cites 'urgent' need to recruit more diverse clinical trial participants

Having children helps parents live longer, especially after age 80

Congress considering partial increase for doctor pay in Medicare

focus

entertainment

hotspot

Cancer drug shortages should be causing more outrage

Explaining an after

Anesthesiologist group: stop taking Ozempic before surgery

Long Covid research funding gets a major boost from NIH

Hollywood unions extend contract negotiations for actors

Why Eli Lilly’s earnings didn’t quite live up to the hype

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Coloradans with cystic fibrosis could lose access to Trikafta

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

explore

All of Us, NIH's precision medicine initiative, gets a big boost

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Resistance to opioid

Having children helps parents live longer, especially after age 80

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

entertainment

knowledge

explore

hotspot